Soft tissue sarcomas and p53 mutations

Molecular Medicine

Volumn 4, Issue 6, 1998, Pages 365-372

  Taubert, Helge ^a   Meye, Axel ^a   Würl, Peter ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; GENE MUTATION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SOFT TISSUE SARCOMA;

EID: 0031841402     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401743     Document Type: Short Survey

References (88)

1. Enzinger FM, Weiss SW. (1995) Soft Tissue Tumors. Mosby, St. Louis, MO.
2. Coindre JM, Trojani M, Contesso G, et al. (1986) Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58: 306-309.
3. Van Unnik JAM, Coindre JM, Contesso G, et al. (1988) In: Ryan JR, Baker LO (eds). Experience of the EORTC Soft Tissue and Bone Sarcoma Treatment. Kluwer Academic Publishers, Dordrecht, pp. 7-13.
4. Markhede G, Angervall L, Stener B. (1982) A multivariate analysis of the prognosis after surgical treatment of malignant soft tissue tumors. Cancer 49: 1721-1733.
5. Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J, Hajdu SI. (1991) The role of multimodality therapy in soft-tissue sarcoma. Ann. Surg. 214: 328-338.
6. Singer S, Corson JM, Gonin R, Labow B, Eberlein TJ. (1994) Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann. Surg. 219: 165-173.
7. Singer S, Corson JM, Demetri GD, Healey EA, Marcus K, Eberlein TJ. (1995) Prognostic factors predictive of survival for truncal and retroperitoneal soft tissue sarcoma. Ann. Surg. 221: 185-195.
8. Suit HD, Mankin HJ, Wood WC, et al. (1988) Treatment of the patient stage MO soft tissue sarcoma. J. Clin. Oncol. 6: 854.
9. Coindre JM, Terrier P, Bui NB, et al. (1996) Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J. Clin. Oncol. 14: 869-877.
10. Foulds L. (1958) The natural history of cancer. J. Chronic Dis. 8: 2-37.
11. Weinberg RA. (1989) Oncogenes, antioncogenes, and the molecular basis of multistep cardnogenesis. Cancer Res. 49: 3713-3721.
12. Bishop JM. (1989) The molecular genetics of cancer. Science 235: 305-311.
13. Vogelstein B, Kinzler KW. (1993) The multistep nature of cancer. Trends Genet. 9: 138-141.
14. Hahn SA, Kern SE, Schmiegel W-H. (1997) Neue molekularbiologische Erkenntnisse aus der Pankreaskarzinom-Forschung. Dt. Ärztebl. 94: 2440-2446.
15. Fearon ER, Vogelstein B. (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
16. Harris CC. (1996a) Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88: 1442-1455.
17. Gottlieb MG, Oren M. (1996) p53 in growth control and neoplasie. Biochem. Biophys. Acta 1287: 77-102.
18. Ozbun M, Butel JS. (1995) Tumorsuppressor p53 mutations and breast cancer: a critical analysis. Adv. Cancer Res. 66: 71-141.
19. Levine AJ. (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
20. Almog N, Rotter V. (1997) Involvement of p53 in cell differentiation and development. Biochem. Biophys. Acta 1333: F1-27.
21. Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991) p53 mutations in human cancers. Science 253: 49-53.
22. Harris CC, Hollstein M. (1993) Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329: 1318-1327.
23. Cordon-Cardo C, Latres E, Drobnjak M, et al. (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54: 794-799.
24. Kleihues P, Schäuble B, zur Hausen A, Esteve J, Ohgaki H (1997) Tumors associated with p53 germline mutations. A synopsis of 91 families. Am. J. Pathol. 150: 1-13.
25. Hainaut P, Soussi T, Shomer B, et al. (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucl. Acids Res. 25: 151-157.
26. Roessner A, Schneider-Stock R, Radig K, Neumann W, Mittler U. (1997) Alterations of p53 gene in soft tissue and bone tumors. Genet. Diagn. Pathol. 143: 1-13.
27. Taubert H, Schmidt H, Würl P, et al. (1997) Morphological and molecular characterization of an undifferentiated soft tissue sarcoma cell line and derivative clones. Int. J. Oncol. 11: 521-526.
28. Yoo J, Lee HK, Kang C, Park WS, Lee JY, Shim SI. (1997) p53 mutations and p53 expression in human soft tissue sarcomas. Arch. Pathol. Lab. Med. 121: 395-399.
29. Malkin D, Li FP, Strong LC, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
30. Malkin D, Jolly KW, Barbier N, et al. (1992) Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N. Engl. J. Med. 326: 1309-1315.
31. Levine AJ. (1993) The p53 tumor suppressor gene and product. Biol. Chem. Hoppe-Seyler 374: 227-235.
32. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355.
33. Prives C. (1994) How loops, sheets, and helices help us to understand p53. Cell 78: 543-546.
34. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1: 1029-1034.
35. Goh HS, Yao J, Smith DR. (1995) P53 point mutation and survival in colorectal cancer patients. Cancer Res. 55: 5217-5221.
36. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428.
37. Aguilar F, Hussain SP, Cerutti P. (1993) Aflatoxin B1 induces the transversion of G to T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 90: 8586-8590.
38. Hollstein MC, Wild CP, Bleicher F, et al. (1993) p53 mutations and aflatoxin B exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer 53: 51-55.
39. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M. (1994) p53 mutation hotspot in radon associated lung cancer. Lancet 343: 86-87.
40. Hussain SP, Kennedy CH, Amstad P, Liu H, Lechner JF, Harris CC (1996) Radon and lung carcinogenesis mutability of p53 codons 249 and 250 to 238Pu alpha particles in human bronchial epithelial cells. Carcinogenesis 18: 121-125.
41. Bartsch H, Hollstein M, Mustonen R, et al. (1995) Screening for putative radon-specific p53 mutation hotspot in German uranium miners. Lancet 346: 121.
42. Hollstein M, Bartsch H, Wesch H, et al. (1997) p53 mutation analysis in tumors of patients exposed to a-particles. Carcinogenesis 18: 511-516.
43. Denissenko MF, Pao A, Tang M, Pfeifer GP. (1996) Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in p53. Science 274: 430-432.
44. Aas T, Borresen AL, Geisler S, et al. (1996) Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2: 811-813.
45. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.
46. Lin J, Wu X, Chen J, Chang A, Levine AJ. (1995) Functions of the p53 protein in growth regulation and tumor suppression. Cold Spring Harb. Symp. Quant. Biol. 59: 215-223.
47. Walker KK, Levine AJ. (1996) Identification of a novel p53 functional domain which is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. U.S.A. 93: 15335-15340.
48. Liu FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. (1994) Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet. Gynecol. 83: 118-124.
49. Taubert H, Meye A, Würl P. (1996) Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 56: 4134-4136.
50. Castresana JS, Ruhio MP, Gomez L, Kreicbergs A, Zetterberg A, Barrios C. (1995) Detection of TP53 gene mutations in human sarcomas. Eur. J. Cancer 1: 735-738.
51. Greenblatt MS, Grollman AP, Harris CC. (1996) Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res. 56: 2130-2136.
52. Milner J, Medcalf EA, Cook A. (1991) Tumor suppressor gene p53: analysis of wild-type and mutant p53 complexes. Mol. Cell. Biol. 11: 12-19.
53. Shaulian E, Zauberman A, Ginsberg D, Oren M. (1992) Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence specific DNA-binding. Mol. Cell. Biol. 12: 5581-5592.
54. Dittmer D, Levine AJ. (1993) Gain function mutations in p53. Nat. Genet. 4: 42-46.
55. Dumaz N, Stary A, Soussi T, Daya-Grosjean L, Sarasin A. (1994) Can we predict solar ultraviolet radiation as the causal event in human tumors by analysing the mutation spectra of the p53 gene? Mutat. Res. 307: 373-386.
56. Lindahl T, Nyberg B. (1974) Heat induced deamination of cytosine resiues in deoxyribonucleic acids. Biochemistry 13: 3405-3410.
57. Coulondre C, Miller JH, Farabough PJ, Gilbert W. (1978) Molecular basis of base substitution hotspots in Escherichia coli. Nature 274: 775-780.
58. Oshima H, Bartsch H. (1994) Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Muttat. Res. 305: 253-264.
59. Schmutte C, Yang AS, Beart RW, Jones PA. (1995) Base repair of U:G mismatches at hotspot in the p53 gene is more efficient than base excision repair of T:G mismatches in extracts of human colon tumors. Cancer Res. 55: 3742-3746.
60. Cooper DN, Youssoufian H. (1988) The CpG nucleotide and human genetic disease. Hum. Genet. 78: 151-158.
61. Koch WM, Brennan JA, Zahurak M, et al. (1996) p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88: 1580-1586.
62. Miyamoto H, Shuin T, Ikeda I, Hosaka M, Kubota Y. (1997) Loss of heterozygosity at the p53, RB, DCC and APC tumor suppressor gene loci in human bladder cancer. J. Urol. 155: 1444-1447.
63. Yamaguchi T, Toguchida J, Wadayama B, Kanoe H, Nakayama T, Ishizaki K, Ikenaga M, Kotoura Y, Sasaki MS. (1997) Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Res. 16: 2009-2015.
64. Montesano R, Hollstein M, Hainaut P. (1996) Genetic alterations in esophageal cancer and their relevance to ethiology and pathogenesis: a review. Int. J. Cancer 69: 225-235.
65. Taubert H, Würl P, Meye A, et al. (1995) Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer 76: 1187-1196.
66. Würl P, Taubert H, Bache M, et al. (1996) Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int. J. Cancer 69: 317-323.
67. Gustafson P. (1994) Soft tissue sarcoma epidemiology and prognosis in 508 patients. Acta Orthop. Scand. 65: 1-31.
68. Lee JM, Bernstein A. (1993) p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. U.S.A. 90: 5742-5746.
69. Lowe SW, Schmitt EM, Smith SE, Osborne BA, Jacks T. (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
70. Clarke AR, Purdie CA, Harrison DJ, et al. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852.
71. Xia F, Wang YH, Tsang NM, Yandell DW, Kelsey KT, Liber HL. (1995) Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res. 55: 12-15.
72. Lowe SW, Ruley HE, Jacks T, Housman DE. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967.
73. Lowe SW, Bodis S, McClatchey A, et al. (1994) p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810.
74. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. (1993) Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 55: 4164-4168.
75. Hawkins DD, Deniers GW, Galloway D. (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56: 892-898.
76. Servomaa K, Kiuru A, Grenman R, Pekkola-Heino K, Pulkkinen JO, Rytomaa T. (1996) p53 mutations with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Prolif. 29: 219-230.
77. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW, Galloway DA. (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med. 2: 72-79.
78. Han Z, Chatterjee D, He DM, Early J, Pantazis P, Wyche JH, Hendrickson EA. (1995) Evidence for a G2 checkpoint in p53-independcnt apoptosis induction by X-irradiation. Mol. Cell. Biol. 15: 5849-5857.
79. Bracey TS, Miller JC, Preece A, Parasevska C. (1995) Gamma-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell line can occur in the absence of wild type p53. Oncogene 10: 2391-2396.
80. Merritt AJ, Allen TD, Potten CS, Hickman JA. (1997) Apoptosis in small intestinal epithelial from p53-null mice: evidence for delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene 14: 2759-2766.
81. O'Connor PM, Jackman J, Bae I, et al. (1997) Characterization of the p53 tumorsuppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57: 4285-4300.
82. Barak Y, Juven T, Haffner R, Oren M. (1993) Mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468.
83. Wu X, Bayle H. Olson D, Levine AJ. (1993) The p53-mdm2 autoregularory feedback loop. Genes Dev. 7: 1126-1132.
84. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83.
85. Ladanyi M, Cha C, Lewis R, Jahnwar SC, Huvos AG, Healey JA. (1993) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53: 16-18.
86. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med. 2: 912-917.
87. Würl P, Meye A, Berger D, et al. (1997) Prognostic relevance of C-terminal MDM2 detection is enhanced by positivity in soft tissue sarcomas. Diagn. Mol. Pathol. 6: 249-254.
88. Würl P, Meye A, Schmidt H, et al. (1998) High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 16: 1183-1185.